The present disclosure generally relates to the treatment of cancer, and in particular to treatment of brain cancer via electric field generation.
Alternating electric field therapy, is a type of electromagnetic field therapy which uses low-intensity electrical fields to treat brain cancer tumors; glioblastoma in particular. Conventional cancer treatments include chemotherapy and radiation, which are associated with treatment-related toxicity and high rates of tumor recurrence. TTF uses an alternating electric field to disrupt cell division in cancer cells, thereby inhibiting cellular replication and initiating apoptosis (cell death). However, some topical TTF treatment methodologies are associated with skin irritation and rashes, as well as a requirement of the patient to maintain a shaved head and restrict physical activity.
It is with these observations in mind, among others, that various aspects of the present disclosure were conceived and developed.
Corresponding reference characters indicate corresponding elements among the view of the drawings. The headings used in the figures do not limit the scope of the claims.
Alternating electric field application is a burgeoning cancer treatment type with the potential to reduce treatment related toxicity. In alternating electric field application, an alternating electric field is applied to a cancerous region of the brain, thereby disrupting cellular division for rapidly-dividing cancer cells. To administer alternating electric field treatment to a patient, a system and method for an alternating electric field generation apparatus, herein referred to as “the present system”, for generating an alternating electric field of optimized strength at a desired location within a body to inhibit cellular division and/or initiate apoptosis of cancer cells at the targeted treatment location is disclosed herein.
The present system provides, among other aspects, a system and method of a subdural implant apparatus wherein, through the use of a array of subdural electrodes implanted subdurally and deep-stimulating electrodes implanted deep into the brain tissue, a targeted alternating electric field is generated for the treatment of rapidly dividing cancer cells. In one aspect, the array of stimulating electrodes is in operative communication with a controller module, wherein the controller module produces a waveform to create the alternating electric field and receives feedback from the array of stimulating electrodes. Referring to the drawings, embodiments of the present system are generally indicated as 100 in
Referring to
The main array 101 may include a plurality of subdural electrodes 103 as well as a plurality of deep-stimulating electrodes 104, such that the subdural electrodes 103 and deep-stimulating electrodes 104 are operable to generate an alternating electric field that is applied to brain tissue. In one aspect, the alternating electric field is configured for appropriate strength and distribution such that cancerous cells in contact with the alternating electric field are prevented from dividing. In some embodiments, one or more wires 102, each defining a respective distal end, extend from a respective subdural electrode 103 and terminates in a conductive contact. In one possible application, each of the plurality of subdural electrodes 103 are placed on the surface of the brain. In some embodiments, the subdural electrodes 103 may be thin enough to fit between the dura mater and the brain of the patient and may in some embodiments be surrounded by gel. Each subdural electrode 103 defines a proximal face 105 and a distal face (not shown), wherein the proximal face is in operative association with a distal end of each wire 102 and the distal face includes a transducing contact that is applied to the exterior of the brain. In some embodiments, the deep-stimulating electrodes 104 have elongated rod-shaped members comprising segmented strips of conductive material. The deep-stimulating electrodes 104 are implanted deep into the brain to facilitate penetration of the alternating electric field into the brain tissue. In some embodiments each of the deep-stimulating electrodes 104 defines a distal end and a proximal end, wherein the distal end of each of the deep-stimulating electrodes 104 is implanted into the brain tissue and the proximal end of each of the deep-stimulating electrodes 104 is in operative association with a respective wire 102. In some embodiments, the deep-stimulating electrodes 104 are operable to measure aspects of the alternating electric field applied to various locations within the brain by the main array 101 and communicate measured aspects of the alternating electric field back to the controller module 120. In one aspect, each subdural electrode 103 and deep-stimulating electrode 104 is operable to apply to tissue a current waveform through the wires 102. An alternating electric field is generated by the application of the waveform to the brain from multiple sources.
One visual example of the placement of subdural electrodes 103 and deep-stimulating electrodes 104 relative to a cancerous region of the brain is shown in
Referring to
Empirical research for TTF therapy recommends a 200 kHz standard waveform to be produced by the waveform generator 124 to generate the alternating electric field. Ideal waveform modulation and intensity parameters are determined by the external computer 200 and delivered to the waveform generator 124 through the processing unit 122.
The controller module 120 may also include a wireless communication module 126 that allows communication between the processing unit 122 of the controller module 120 and external computer 200. In this manner, the processing unit 122 of the controller module 120 is operable to wirelessly receive software updates and instructions from the external computer 200 as well as transmit the measured aspects of the alternating electric field to the external computer 200 for review and system optimization. The controller module 120 may also include an implantable battery (not shown) or other power supply.
A method for the treatment of cancer using the system 100 is illustrated in
Referring back to
In some embodiments of the system 100, the simulation environment used in the optimization process using the external computer 200 is operable to obtain the exact positions of the subdural electrodes 103 and the deep-stimulating electrodes 104 as input as well as including information about the alternating electric field strength as measured by the deep-stimulating electrodes 104. In addition, the simulation environment application is operable to allow the user to observe changes in the alternating electric field delivered to the brain by changes in the waveform delivered to any given electrode 103 or 104. As changes in the delivered waveform are simulated, the simulation environment application is operable to optimize the alternating electric field generation by calculating and displaying a distribution of alternating electric field strength throughout the brain as a result of the changes in the delivered waveform, the exact positions of the electrodes 103 and 104, and/or the unique anatomy of the patient's brain. This allows the user to determine the best configuration of electrode stimulation parameters for electrodes 103 and 104 to optimize the alternating electric field in the targeted region. A given parameter may then be initialized in the patient and altered while real-time data is acquired by one or more of the deep-stimulating electrodes 104 in the brain to ensure adequate alternating electric field strength is achieved.
It should be understood from the foregoing that, while particular embodiments have been illustrated and described, various modifications can be made thereto without departing from the spirit and scope of the invention as will be apparent to those skilled in the art. Such changes and modifications are within the scope and teachings of this invention as defined in the claims appended hereto.
This is a continuation application that claims benefit from U.S. 371 National patent application Ser. No. 17/260,019 filed Jan. 13, 2021, which claims the benefit of International Application No. PCT/US2019/042197, filed Jul. 17, 2019, which claims benefit from U.S. provisional application Ser. No. 62/699,146 filed on Jul. 17, 2018, which is incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
6572572 | Pomatto et al. | Jun 2003 | B2 |
8364284 | Barker | Jan 2013 | B2 |
8494627 | Bikson et al. | Jul 2013 | B2 |
8996115 | Trier et al. | Mar 2015 | B2 |
20020010408 | Pomatto et al. | Jan 2002 | A1 |
20070203539 | Stone et al. | Aug 2007 | A1 |
20080046023 | Fischell | Feb 2008 | A1 |
20100070009 | Barker | Mar 2010 | A1 |
20110313236 | Valente et al. | Dec 2011 | A1 |
20120150256 | Martens | Jun 2012 | A1 |
20120203307 | Schroeppel et al. | Aug 2012 | A1 |
20120259382 | Trier et al. | Oct 2012 | A1 |
20120265261 | Bikson et al. | Oct 2012 | A1 |
20160354142 | Pearson et al. | Dec 2016 | A1 |
20170120041 | Wenger | May 2017 | A1 |
20180178013 | Bouton et al. | Jun 2018 | A1 |
20180289954 | Hebb | Oct 2018 | A1 |
20190314631 | Wong | Oct 2019 | A1 |
20210308455 | Hendricks et al. | Oct 2021 | A1 |
Number | Date | Country |
---|---|---|
106823140 | Jun 2017 | CN |
107921257 | Apr 2018 | CN |
2007521076 | Aug 2007 | JP |
2013500115 | Jan 2013 | JP |
2018516149 | Jun 2018 | JP |
2015010682 | Jan 2015 | WO |
2016179712 | Nov 2016 | WO |
2018057953 | Mar 2018 | WO |
Entry |
---|
IP Australia, Examination Report 1, Application No. 2019306571, Mar. 4, 2024, 4 pages. |
China National Intellectual Property Administration, Second Office Action, Application No. 201980047095.3, dated May 13, 2024, 18 pages. |
Japan Patent Office, Notice of Reasons for Rejection, Application No. 2021-501284, Mar. 28, 2023 6 pages. |
China National Intellectual Property Administration, First Office Action, Application No. 201980047095.3, dated Sep. 20, 2023, 18 pages. |
European Patent Office, Extended European Search Report issued in corresponding Application No. 19837750.9, dated Mar. 18, 2022, 6 pages. |
Patent Cooperation Treaty, International Search Report and Written Opinion, International Application No. PCT/US2019/042197, dated Oct. 4, 2019, 13 pages. |
Number | Date | Country | |
---|---|---|---|
20230149713 A1 | May 2023 | US |
Number | Date | Country | |
---|---|---|---|
62699146 | Jul 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17260019 | US | |
Child | 18155849 | US |